A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...

Celltrion, a major South Korean biopharmaceutical firm, on Thursday said it has launched its biosimilar product for Stelara, a ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos' financial outlook, restructuring activities and estimated cash outlook as reported by ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host confer ...

The global allergy treatment industry, valued at US$ 18.9 billion in 2023, is projected to experience substantial growth.

The new bill would also require state Medicaid programs to report National Average Drug Acquisition Costs (NADAC) as a way to ...

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...